Tricuspid regurgitation is a common and impairing disease. Optimal medical therapy (OMT) is limited, valve surgery is complex, and mortality is not low. Dr. Paul Sorajja presented the results of the Pivotal Triluminate study to demonstrate the safety and efficacy of edge-to-edge treatment (transcatheter edge-to-edge repair, TEER) in tricuspid regurgitation. Three hundred and fifty patients…
ACC 2023 | COAPT Study: 5 Year Followup after Transcatheter Repair of Secondary Mitral Regurgitation
The five year outcomes of the multicenter open label COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) were presented at ACC 2023; it included 614 patients with cardiac failure (CF) and moderate to severe (3+/4+) symptomatic secondary mitral regurgitation, despite medical therapy. Patients were randomized 1:1…
Secondary Mitral Regurgitation: Stages of Heart Failure and Prognostic Implications after Transcatheter Edge-to-Edge Repair
We are already familiar with the strong impact of secondary mitral valve regurgitation (SMR) in survival and quality of life. Most of these patients present heart failure (HF) with reduced ejection fraction (HFrEF). Stages of heart failure based on extra-mitral cardiac involvement has been shown relevant. There is also extensive research on aortic valve disease…
Edge-to-Edge Repair Reduces Hospitalization and Mortality Rates in Secondary Mitral Valve Regurgitation?
Severe secondary mitral valve regurgitation is associated to hospitalization and mortality. The COAPT study has shown the superiority of guideline directed medical therapy at maximal tolerated doses according to guidelines (GDMT) plus edge-to-edge transcatheter repair (TEER) versus GMDT alone. However, at present there is no information on the impact of hospitalizations and their relationship to…
A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip
Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone. However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the…
TCT 2022 | Edge-to-Edge Repair in Patients with Severe Mitral Insufficiency and Cardiogenic Shock: Analysis of the TVT Registry
Approximately 1 in 5 patients admitted for cardiogenic shock (CS) were observed to have moderate to severe mitral insufficiency (MI), which increases the risk of mortality by about 60%. To date, there is limited data on the role of transcatheter edge-to-edge repair therapy in this setting. The aim of this study was to describe the…
SOLACI-SOCIME 2022 | Transcatheter treatment of mitral valve regurgitation, by Dr. Luis Nombela Franco
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Luis Nombela Franco, entitled “Transcatheter treatment of mitral valve regurgitation”
SOLACI-SOCIME 2022 | When is indicated the transcatheter treatment of mitral regurgitation
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Márcio Montenegro, entitled “When is indicated the transcatheter treatment of mitral regurgitation”
The Best of the SOLACI-SOCIME 2022 Main Arena: Mitral Valve
During the “Mitral Valve” session (on the first day of the SOLACI-SOCIME 2022 Congress), Dr. Ignacio Amat Santos (SPA) delivered a great talk on transcatheter mitral valve replacement (TMVR). During his presentation, he discussed different scenarios for transcatheter replacement: mitral valve-in-vale, mitral valve-in-ring, mitral valve in MAC, and new devices for non-calcified native valves. When…
Post-MitraClip Mitral Valve Stenosis: Bad Prognosis
The EVEREST II trial has shown the MitraClip has similar mortality rate to that of surgery and, on the other hand, we are well aware that residual mitral regurgitation (MR) is associated with a strong negative impact. However, research has shown little about transvalvular gradient after MitraClip and what it entails. 268 patients receiving MitraClip were…
MitraClip Reduces Renal Function Deterioration
Severe mitral regurgitation is associated to cardiac failure and hospitalization and over time is accompanied by kidney failure, which leads to higher mortality. In the COAPT study, in patients with low ejection fraction, MitraClip showed benefits over medical treatment, but there was an important group of people with kidney function deterioration. The evolution and benefit…